City Therapeutics will join a slew of biotechs that have entered the public markets this year, with a $200 million raise that landed above expectations.
GE HealthCare (Nasdaq: GEHC) today announced the publication of research conducted at the University of Michigan iv ...
PharmaEssentia Corporation (TWSE: 6446), a Taiwan-based biopharmaceutical company, is expanding its global presence through ...
Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...
Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced its ...
Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel ...
Curis, Inc. (Nasdaq: CRIS) ("Curis" or the "Company"), a biotechnology company focused on the development of emavusertib ...
ZILBRYSQ is the first and only macrocyclic peptide C5 inhibitor approved as a self-administered once-daily, subcutaneous ...
Intranasal foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development.
Inconsistent reporting at a Pennsylvania site affected microbiological analyses of components and drug products that ...
The sixth cycle of OrbiMed’s Asia Partners fund included one with more than $1 billion earmarked for life science companies ...
After years of quiet maturation, new approach methodologies and emerging clinical success for cell therapies are fueling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results